Acrivon therapeutics announces acr-2316, a novel dual wee1 and pkmyt1 inhibitor development candidate, designed using acrivon's ap3 platform to achieve potent single agent activity, as demonstrated in preclinical studies

Acrivon's predictive precision proteomics (ap3) platform is a proprietary, broadly applicable, next-generation precision oncology platform at the forefront of the next wave of biology-driven drug discovery, in addition to its previously demonstrated utility in clinical development for treating patients based on predicted drug sensitivity
ACRV Ratings Summary
ACRV Quant Ranking